I tried to put the most important catalysts for Santarus together. Of course don't forget the quarterly numbers which are always helpful for the share price.
Q4 2013 / end of 2013:
- Add approximately 25 sales representatives to the sales force
"We believe the impact of these additional sales efforts will be incrementally positive for sales trends starting in 2014. We expect to have the new sales representatives in place by the fourth quarter of this year."
- Plan to initiate a Phase IIa study with SAN-300 in rheumatoid arthritis by the end of this year.
- Results of CONTRIBUTE study (End of 2013 / early next year)
"We also have completed enrollment of our CONTRIBUTE study with UCERIS as add on to 5-ASA therapy for the induction of remission of ulcerative colitis and expect to report top line data by the end of this year, early next year. We believe these data will provide valuable information for physicians who treat patients with active ulcerative colitis."
- Blood Products Advisory Committee for RUCONEST?
- Ruconest: PDUFA date April 16, 2014
(RUCONEST for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE).